Engineered Cell-Membrane-Coated Nanoparticles Directly Present Tumor Antigens to Promote Anticancer Immunity.
Engineered Cell-Membrane-Coated Nanoparticles Directly Present Tumor Antigens to Promote Anticancer Immunity.
复制标题
工程细胞膜包被纳米颗粒直接呈递肿瘤抗原促进抗癌免疫。
DOI：
10.1002/adma.202001808
复制
发表时间：
2020-07
期刊：
影响因子：
--
通讯作者：
Zhang L
中科院分区：
文献类型：
--
作者：
Jiang Y;Krishnan N;Zhou J;Chekuri S;Wei X;Kroll AV;Yu CL;Duan Y;Gao W;Fang RH;Zhang L
最近免疫疗法的成功凸显了利用免疫系统对抗癌症的力量。为了使大多数基于免疫的疗法取得成功，必须动员具有正确肿瘤靶向特异性的T细胞亚群。当缺乏这种特异性时，为免疫系统提供用于加工和呈递的肿瘤抗原材料是刺激抗原特异性T细胞群的常见策略。虽然原则上很简单，但经验表明，抗原呈递过程的操纵可能非常复杂，需要难以翻译的复杂策略。在此，我们报告了一种仿生纳米颗粒平台的设计，该平台可用于直接刺激T细胞，而不需要专业的抗原呈递细胞。这些纳米颗粒是使用源自癌细胞的细胞膜涂层制造的，所述癌细胞被工程化以表达共刺激标记物。结合膜表面天然呈递的肽表位，最终制剂含有促进肿瘤抗原特异性免疫应答的必要信号，从而引发可用于控制肿瘤生长的T细胞。报道的方法代表了一种新兴的策略，可用于开发多抗原，个性化的癌症免疫疗法。癌细胞经基因工程改造以表达共刺激标志物，所述共刺激标志物使癌细胞能够在免疫刺激环境下将其自身抗原直接呈递给免疫系统。来源于这些修饰的癌细胞的细胞膜包被的纳米颗粒能够在体内引发抗肿瘤免疫，同时绕过传统的细胞介导的抗原呈递的需要。报道的方法最终可用于设计能够动员免疫细胞亚群对抗患者特异性癌症抗原的个性化人工抗原呈递平台。
The recent success of immunotherapies has highlighted the power of leveraging the immune system in the fight against cancer. In order for most immune-based therapies to succeed, T cell subsets with the correct tumor-targeting specificities must be mobilized. When such specificities are lacking, providing the immune system with tumor antigen material for processing and presentation is a common strategy for stimulating antigen-specific T cell populations. While straightforward in principle, experience has shown that manipulation of the antigen presentation process can be incredibly complex, necessitating sophisticated strategies that are difficult to translate. Herein, we report on the design of a biomimetic nanoparticle platform that can be used to directly stimulate T cells without the need for professional antigen-presenting cells. The nanoparticles are fabricated using a cell membrane coating derived from cancer cells engineered to express a costimulatory marker. Combined with the peptide epitopes naturally presented on the membrane surface, the final formulation contains the necessary signals to promote tumor antigen-specific immune responses, priming T cells that can be used to control tumor growth. The reported approach represents an emerging strategy that can be used to develop multi-antigenic, personalized cancer immunotherapies. Cancer cells are genetically engineered to express a co-stimulatory marker that enables them to directly present their own antigens to the immune system under an immunostimulatory context. Cell membrane-coated nanoparticles sourced from these modified cancer cells are able to elicit antitumor immunity in vivo while bypassing the need for traditional cell-mediated antigen presentation. The reported approach may ultimately be used in the design of personalized artificial antigen presentation platforms capable of mobilizing immune cell subsets against patient-specific cancer antigens.
登录
查看更多内容
影响因子：
10.8
作者：
Gao W;Fang RH;Thamphiwatana S;Luk BT;Li J;Angsantikul P;Zhang Q;Hu CM;Zhang L
通讯作者：
Zhang L
影响因子：
7.3
作者：
Awate S;Babiuk LA;Mutwiri G
通讯作者：
Mutwiri G
DOI：
10.1084/jem.20160801
发表时间：
2017-04-03
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Juneja VR;McGuire KA;Manguso RT;LaFleur MW;Collins N;Haining WN;Freeman GJ;Sharpe AH
通讯作者：
Sharpe AH
一种吸收孔形成毒素的仿生纳米质体。
影响因子：
38.3
作者：
通讯作者：
--
影响因子：
38.3
作者：
通讯作者：
--